AHAnna E. Howell

Anna E. Howell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna E. Howell has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Anaiis Zaratzian

    Cancer Ecosystems Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia

    2 shared publications
  • Andrew Da Silva

    Cancer Ecosystems Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia

    2 shared publications
  • Anthony J. Gill

    Sydney Medical School, University of Sydney, Sydney

    2 shared publications
  • Antonia L. Cadell

    Garvan Institute of Medical Research, Sydney, NSW 2010, Australia

    2 shared publications
  • Astrid Magenau

    Cancer Ecosystems Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia

    2 shared publications
  • Australian Pancreatic Cancer Genome Initiative (Apgi)

    2 shared publications

Latest Publications

  • Open Access

    Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis

    by Cecilia R. Chambers, Supitchaya Watakul, Peter Schofield, Anna E. Howell, Jessie Zhu, Alice M. H. Tran, Nadia Kuepper, Daniel A. Reed, Kendelle J. Murphy, Lily M. Channon, et al.

    Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and NPY1R are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP R172H C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of Npy1r significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP R172H C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.


  • Open Access

    Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response

    by Brooke A. Pereira, Shona Ritchie, Cecilia R. Chambers, Katie A. Gordon, Astrid Magenau, Kendelle J. Murphy, Max Nobis, Victoria M. Tyma, Ying Fei Liew, Morghan C. Lucas, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC ( Pdx1-Cre , LSL-Kras G12D/+ , LSL-Trp53 R172H/+ ) and poorly metastatic KP fl C ( Pdx1-Cre , LSL-Kras G12D/+ , Trp53 fl/+ ) genetically engineered mouse models of pancreatic cancer using mass spectrometry proteomics. Our assessment at early-, mid-, and late-stage disease reveals an increased abundance of nidogen-2 (NID2) in the KPC model compared to KP fl C, with further validation showing that NID2 is primarily expressed by cancer-associated fibroblasts (CAFs). Using biomechanical assessments, second harmonic generation imaging, and birefringence analysis, we show that NID2 reduction by CRISPR interference (CRISPRi) in CAFs reduces stiffness and matrix remodeling in three-dimensional models, leading to impaired cancer cell invasion. Intravital imaging revealed improved vascular patency in live NID2-depleted tumors, with enhanced response to gemcitabine/Abraxane. In orthotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NID2 as a potential PDAC cotarget.